Spruce Street Capital LP Purchases Shares of 2,198,502 SAB Biotherapeutics, Inc. $SABS

Spruce Street Capital LP purchased a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 2,198,502 shares of the company’s stock, valued at approximately $8,222,000. SAB Biotherapeutics accounts for about 2.7% of Spruce Street Capital LP’s portfolio, making the stock its 13th largest holding.

Several other hedge funds also recently added to or reduced their stakes in the business. State of Wyoming purchased a new stake in SAB Biotherapeutics in the fourth quarter valued at $34,000. State Street Corp purchased a new stake in SAB Biotherapeutics in the fourth quarter valued at $49,000. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics in the third quarter valued at $30,000. Fifth Lane Capital LP purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth about $56,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $32,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Trading Up 17.1%

SABS stock opened at $3.90 on Tuesday. SAB Biotherapeutics, Inc. has a 52-week low of $1.65 and a 52-week high of $6.60. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. The company’s 50-day simple moving average is $3.70 and its 200-day simple moving average is $3.85. The firm has a market cap of $298.19 million, a P/E ratio of -1.85 and a beta of 0.54.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). As a group, equities analysts forecast that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Leerink Partners increased their target price on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday. Jefferies Financial Group assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, May 20th. They set a “buy” rating and a $11.00 target price on the stock. Rodman & Renshaw reissued a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of SAB Biotherapeutics in a research note on Monday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $11.63.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.